Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Article in English | MEDLINE | ID: mdl-29555632

ABSTRACT

For an increasing number of antimalarial agents identified in high-throughput phenotypic screens, there is evidence that they target PfATP4, a putative Na+ efflux transporter on the plasma membrane of the human malaria parasite Plasmodium falciparum For several such "PfATP4-associated" compounds, it has been noted that their addition to parasitized erythrocytes results in cell swelling. Here we show that six structurally diverse PfATP4-associated compounds, including the clinical candidate KAE609 (cipargamin), induce swelling of both isolated blood-stage parasites and intact parasitized erythrocytes. The swelling of isolated parasites is dependent on the presence of Na+ in the external environment and may be attributed to the osmotic consequences of Na+ uptake. The swelling of the parasitized erythrocyte results in an increase in its osmotic fragility. Countering cell swelling by increasing the osmolarity of the extracellular medium reduces the antiplasmodial efficacy of PfATP4-associated compounds, consistent with cell swelling playing a role in the antimalarial activity of this class of compounds.


Subject(s)
Antimalarials/pharmacology , Biological Transport, Active/drug effects , Cell Size/drug effects , Indoles/pharmacology , Malaria, Falciparum/drug therapy , Membrane Transport Proteins/drug effects , Plasmodium falciparum/drug effects , Plasmodium falciparum/growth & development , Spiro Compounds/pharmacology , Erythrocytes/parasitology , Humans , Osmotic Fragility/drug effects
2.
J Nat Prod ; 80(1): 114-125, 2017 01 27.
Article in English | MEDLINE | ID: mdl-28001067

ABSTRACT

Thirteen new metabolites, including the polyoxygenated cyclohexene derivatives cleistodiendiol (1), cleistodienol B (3), cleistenechlorohydrins A (4) and B (5), cleistenediols A-F (6-11), cleistenonal (12), and the butenolide cleistanolate (13), 2,5-dihydroxybenzyl benzoate (cleistophenolide, 14), and eight known compounds (2, 15-21) were isolated from a MeOH extract of the leaves of Cleistochlamys kirkii. The purified metabolites were identified by NMR spectroscopic and mass spectrometric analyses, whereas the absolute configurations of compounds 1, 17, and 19 were established by single-crystal X-ray diffraction. The configuration of the exocyclic double bond of compound 2 was revised based on comparison of its NMR spectroscopic features and optical rotation to those of 1, for which the configuration was determined by X-ray diffraction. Observation of the co-occurrence of cyclohexenoids and heptenolides in C. kirkii is of biogenetic and chemotaxonomic significance. Some of the isolated compounds showed activity against Plasmodium falciparum (3D7, Dd2), with IC50 values of 0.2-40 µM, and against HEK293 mammalian cells (IC50 2.7-3.6 µM). While the crude extract was inactive at 100 µg/mL against the MDA-MB-231 triple-negative breast cancer cell line, some of its isolated constituents demonstrated cytotoxic activity with IC50 values ranging from 0.03-8.2 µM. Compound 1 showed the most potent antiplasmodial (IC50 0.2 µM) and cytotoxic (IC50 0.03 µM, MDA-MB-231 cell line) activities. None of the compounds investigated exhibited translational inhibitory activity in vitro at 20 µM.


Subject(s)
Antimalarials/isolation & purification , Antimalarials/pharmacology , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Breast Neoplasms/chemistry , Breast Neoplasms/drug therapy , Cyclohexenes/isolation & purification , Cyclohexenes/pharmacology , HEK293 Cells/pathology , Plant Leaves/chemistry , Plasmodium falciparum/drug effects , Antimalarials/chemistry , Antineoplastic Agents, Phytogenic/chemistry , Cyclohexenes/chemistry , HEK293 Cells/chemistry , Humans , Inhibitory Concentration 50 , Molecular Structure , X-Ray Diffraction
3.
Parasit Vectors ; 9(1): 589, 2016 11 17.
Article in English | MEDLINE | ID: mdl-27855724

ABSTRACT

BACKGROUND: In the fight against malaria, the discovery of chemical compounds with a novel mode of action and/or chemistry distinct from currently used drugs is vital to counteract the parasite's known ability to develop drug resistance. Another desirable aspect is efficacy against gametocytes, the sexual developmental stage of the parasite which enables the transmission through Anopheles vectors. Using a chemical rescue approach, we previously identified compounds targeting Plasmodium falciparum coenzyme A (CoA) synthesis or utilization, a promising target that has not yet been exploited in anti-malarial drug development. RESULTS: We report on the outcomes of a series of biological tests that help to define the species- and stage-specificity, as well as the potential targets of these chemically diverse compounds. Compound activity against P. falciparum gametocytes was determined to assess stage-specificity and transmission-reducing potential. Against early stage gametocytes IC50 values ranging between 60 nM and 7.5 µM were obtained. With the exception of two compounds with sub-micromolar potencies across all intra-erythrocytic stages, activity against late stage gametocytes was lower. None of the compounds were specific pantothenate kinase inhibitors. Chemical rescue profiling with CoA pathway intermediates demonstrated that most compounds acted on either of the two final P. falciparum CoA synthesis enzymes, phosphopantetheine adenylyltransferase (PPAT) or dephospho CoA kinase (DPCK). The most active compound targeted either phosphopantothenoylcysteine synthetase (PPCS) or phosphopantothenoylcysteine decarboxylase (PPCDC). Species-specificity was evaluated against Trypanosoma cruzi and Trypanosoma brucei brucei. No specific activity against T. cruzi amastigotes was observed; however three compounds inhibited the viability of trypomastigotes with sub-micromolar potencies and were confirmed to act on T. b. brucei CoA synthesis. CONCLUSIONS: Utilizing the compounds we previously identified as effective against asexual P. falciparum, we demonstrate for the first time that gametocytes, like the asexual stages, depend on CoA, with two compounds exhibiting sub-micromolar potencies across asexual forms and all gametocytes stages tested. Furthermore, three compounds inhibited the viability of T. cruzi and T. b. brucei trypomastigotes with sub-micromolar potencies and were confirmed to act on T. b. brucei CoA synthesis, indicating that the CoA synthesis pathway might represent a valuable new drug target in these parasite species.


Subject(s)
Antimalarials/pharmacology , Coenzyme A/metabolism , Metabolic Networks and Pathways/drug effects , Plasmodium falciparum/drug effects , Cell Survival/drug effects , Enzyme Inhibitors/pharmacology , Inhibitory Concentration 50 , Trypanosoma brucei brucei/drug effects , Trypanosoma brucei brucei/physiology , Trypanosoma cruzi/drug effects , Trypanosoma cruzi/physiology
4.
Nat Protoc ; 11(5): 976-92, 2016 May.
Article in English | MEDLINE | ID: mdl-27123949

ABSTRACT

The tightly controlled induction of Plasmodium falciparum gametocytes in large-scale culture is a fundamental requirement for malaria drug discovery applications including, but not limited to, high-throughput screening. This protocol uses magnetic separation for isolation of hemozoin-containing parasites in order to (i) increase parasitemia, (ii) decrease hematocrit and (iii) introduce higher levels of young red blood cells in a culture simultaneously within 2-4 h. These parameters, along with red blood cell lysis products that are generated through schizont rupture, are highly relevant for enabling optimum induction of gametocytogenesis in vitro. No other previously published protocols have applied this particular approach for parasite isolation and maximization of fresh red blood cells before inducing gametocytogenesis, which is essential for obtaining highly synchronous gametocyte classical stages on a large scale. In summary, 500-1,000 million stage IV gametocytes can be obtained within 16 d from an initial 10 ml of asexual blood-stage culture.


Subject(s)
Erythrocytes/parasitology , Microbiological Techniques/methods , Plasmodium falciparum , Germ Cells , Hematocrit , High-Throughput Screening Assays/methods , Humans , Immunomagnetic Separation/instrumentation , Immunomagnetic Separation/methods , Plasmodium falciparum/isolation & purification , Workflow
5.
Eur J Med Chem ; 110: 43-64, 2016 Mar 03.
Article in English | MEDLINE | ID: mdl-26807544

ABSTRACT

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.


Subject(s)
Aminopeptidases/antagonists & inhibitors , Antimalarials/pharmacology , Hydroxamic Acids/pharmacology , Plasmodium falciparum/drug effects , Protease Inhibitors/pharmacology , Protozoan Proteins/antagonists & inhibitors , Aminopeptidases/chemistry , Aminopeptidases/metabolism , Antimalarials/chemistry , HEK293 Cells , Humans , Hydroxamic Acids/chemistry , Malaria, Falciparum/drug therapy , Models, Molecular , Protease Inhibitors/chemistry , Protozoan Proteins/chemistry , Protozoan Proteins/metabolism , Structure-Activity Relationship , Zinc/metabolism
6.
Antimicrob Agents Chemother ; 59(7): 4206-14, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25941228

ABSTRACT

Plasmodium falciparum is transmitted from humans to Anopheles mosquito vectors via the sexual erythrocytic forms termed gametocytes. Erythrocyte filtration through microsphere layers (microsphiltration) had shown that circulating gametocytes are deformable. Compounds reducing gametocyte deformability would induce their splenic clearance, thus removing them from the blood circulation and blocking malaria transmission. The hand-made, single-sample prototype for microsphiltration was miniaturized to a 96-well microtiter plate format, and gametocyte retention in the microsphere filters was quantified by high-content imaging. The stiffening activity of 40 pharmacological compounds was assessed in microtiter plates, using a small molecule (calyculin) as a positive control. The stiffening activity of calyculin was assessed in spleen-mimetic microfluidic chips and in macrophage-depleted mice. Marked mechanical retention (80% to 90%) of mature gametocytes was obtained in microplates following exposure to calyculin at concentrations with no effect on parasite viability. Of the 40 compounds tested, including 20 antimalarials, only 5 endoperoxides significantly increased gametocyte retention (1.5- to 2.5-fold; 24 h of exposure at 1 µM). Mature gametocytes exposed to calyculin accumulated in microfluidic chips and were cleared from the circulation of macrophage-depleted mice as rapidly as heat-stiffened erythrocytes, thus confirming results obtained using the microsphiltration assay. An automated miniaturized approach to select compounds for their gametocyte-stiffening effect has been established. Stiffening induces gametocyte clearance both in vitro and in vivo. Based on physiologically validated tools, this screening cascade can identify novel compounds and uncover new targets to block malaria transmission. Innovative applications in hematology are also envisioned.


Subject(s)
Malaria, Falciparum/parasitology , Malaria, Falciparum/transmission , Plasmodium falciparum/growth & development , Spleen/parasitology , Animals , Antimalarials/pharmacology , Automation , Enzyme Inhibitors/pharmacology , Erythrocyte Count , Erythrocytes/parasitology , Filtration , Flow Cytometry , Image Processing, Computer-Assisted , Macrophages/parasitology , Malaria, Falciparum/prevention & control , Marine Toxins , Mice , Microfluidic Analytical Techniques , Microspheres , Models, Biological , Oxazoles/pharmacology , Parasite Egg Count , Spleen/drug effects
7.
J Nat Prod ; 78(4): 914-8, 2015 Apr 24.
Article in English | MEDLINE | ID: mdl-25803573

ABSTRACT

The fungal metabolite 3-chloro-4-hydroxyphenylacetic acid (1) was utilized in the generation of a unique drug-like screening library using parallel solution-phase synthesis. A 20-membered amide library (3-22) was generated by first converting 1 to methyl (3-chloro-4-hydroxyphenyl)acetate (2), then reacting this scaffold with a diverse series of primary amines via a solvent-free aminolysis procedure. The structures of the synthetic analogues (3-22) were elucidated by spectroscopic data analysis. The structures of compounds 8, 12, and 22 were confirmed by single X-ray crystallographic analysis. All compounds were evaluated for cytotoxicity against a human prostate cancer cell line (LNCaP) and for antiparasitic activity toward Trypanosoma brucei brucei and Plasmodium falciparum and showed no significant activity at 10 µM. The library was also tested for effects on the lipid content of LNCaP and PC-3 prostate cancer cells, and it was demonstrated that the fluorobenzyl analogues (12-14) significantly reduced cellular phospholipid and neutral lipid levels.


Subject(s)
Biological Products/chemical synthesis , Phenylacetates/chemistry , Antimalarials/pharmacology , Biological Products/chemistry , Combinatorial Chemistry Techniques , Crystallography, X-Ray , Humans , Male , Molecular Conformation , Molecular Structure , Nuclear Magnetic Resonance, Biomolecular , Phenylacetates/chemical synthesis , Plasmodium falciparum/drug effects , Structure-Activity Relationship , Trypanosoma brucei brucei/drug effects
8.
J Cell Sci ; 126(Pt 12): 2692-703, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23572510

ABSTRACT

Efficient trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) to and from the cell surface is essential for maintaining channel density at the plasma membrane (PM) and ensuring proper physiological activity. The most common mutation, F508del, exhibits reduced surface expression and impaired function despite treatment with currently available pharmacological small molecules, called correctors. To gain more detailed insight into whether CFTR enters compartments that allow corrector stabilization in the cell periphery, we investigated the peripheral trafficking itineraries and kinetics of wild type (WT) and F508del in living cells using high-speed fluorescence microscopy together with fluorogen activating protein detection. We directly visualized internalization and accumulation of CFTR WT from the PM to a perinuclear compartment that colocalized with the endosomal recycling compartment (ERC) markers Rab11 and EHD1, reaching steady-state distribution by 25 minutes. Stimulation by protein kinase A (PKA) depleted this intracellular pool and redistributed CFTR channels to the cell surface, elicited by reduced endocytosis and active translocation to the PM. Corrector or temperature rescue of F508del also resulted in targeting to the ERC and exhibited subsequent PKA-stimulated trafficking to the PM. Corrector treatment (24 hours) led to persistent residence of F508del in the ERC, while thermally destabilized F508del was targeted to lysosomal compartments by 3 hours. Acute addition of individual correctors, C4 or C18, acted on peripheral trafficking steps to partially block lysosomal targeting of thermally destabilized F508del. Taken together, corrector treatment redirects F508del trafficking from a degradative pathway to a regulated recycling route, and proteins that mediate this process become potential targets for improving the efficacy of current and future correctors.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Mutation , Cell Line , Cell Membrane/drug effects , Cell Membrane/genetics , Cell Membrane/metabolism , Cyclic AMP-Dependent Protein Kinases/genetics , Cyclic AMP-Dependent Protein Kinases/metabolism , Endocytosis/genetics , Endocytosis/physiology , Endosomes/genetics , Endosomes/metabolism , Endosomes/physiology , HEK293 Cells , Humans , Lysosomes/genetics , Lysosomes/metabolism , Lysosomes/physiology , Microscopy, Fluorescence/methods , Protein Transport , Proteolysis , Vesicular Transport Proteins/genetics , Vesicular Transport Proteins/metabolism , rab GTP-Binding Proteins/genetics , rab GTP-Binding Proteins/metabolism
9.
Mol Med ; 18: 685-96, 2012 May 09.
Article in English | MEDLINE | ID: mdl-22396015

ABSTRACT

Numerous human diseases arise because of defects in protein folding, leading to their degradation in the endoplasmic reticulum. Among them is cystic fibrosis (CF), caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR ), an epithelial anion channel. The most common mutation, F508del, disrupts CFTR folding, which blocks its trafficking to the plasma membrane. We developed a fluorescence detection platform using fluorogen-activating proteins (FAPs) to directly detect FAP-CFTR trafficking to the cell surface using a cell-impermeant probe. By using this approach, we determined the efficacy of new corrector compounds, both alone and in combination, to rescue F508del-CFTR to the plasma membrane. Combinations of correctors produced additive or synergistic effects, improving the density of mutant CFTR at the cell surface up to ninefold over a single-compound treatment. The results correlated closely with assays of stimulated anion transport performed in polarized human bronchial epithelia that endogenously express F508del-CFTR. These findings indicate that the FAP-tagged constructs faithfully report mutant CFTR correction activity and that this approach should be useful as a screening assay in diseases that impair protein trafficking to the cell surface.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/genetics , Drug Evaluation, Preclinical/methods , Microscopy, Fluorescence , Mutation , Cell Line , Cell Membrane/metabolism , Cystic Fibrosis/metabolism , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Gene Expression , Genes, Reporter , Humans , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Staining and Labeling
SELECTION OF CITATIONS
SEARCH DETAIL
...